SSelectStock

MEDICOMedico Remedies Limited

Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)

Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India. The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics; antimalarials; dry syrups; ointments and creams; anti-diabetics; syrups; and miscellaneous products, as well as diuretics, antireterovirals, and steroidal preparations. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India.

37.05
4.60%
46Average

Mkt Cap
₹307 Cr
P/E
22.3
P/B
4.0
Div Yield
0.00%
52W High
₹56.88
52W Low
₹30.22

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)306.80
P/E22.32
P/B4.02
PEG0.60
ROE %17.40
ROCE %14.70
Debt / Equity0.25
EPS1.66
Revenue Growth %81.40
Profit Growth %36.40
Dividend Yield %0.00
Promoter Holding %69.45
FII Holding %0.00
DII Holding %
Beta0.65

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

HOLDConviction 53%

The picture

  • Revenue growth: 81.4% YoY
  • Profit growth: 36.4% YoY
  • ROE: 17.4%
  • Volume: 3.2x 20-day average
  • Volume trend: 1.9x baseline
  • Sector momentum: sector +6.2% (1m)
  • Bullish Engulfing signal (setup quality 77%)
  • RSI Oversold Reversal signal (setup quality 62%)

Bull case

  • Revenue growth: 81.4% YoY
  • Profit growth: 36.4% YoY
  • ROE: 17.4%
  • Volume: 3.2x 20-day average

Bear case

  • Dividend yield: 0.00%
  • RSI: 36
  • MACD: bearish
  • 1-month return: -22.6%

Key risks

  • Elevated volatility / drawdown profile — size positions accordingly
  • Momentum is fading versus the broader market
  • Dividend yield: 0.00%
  • RSI: 36

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹37.05
Stop Loss
₹33.77
risk 8.9%
Target 1 (1.5R)
₹41.97
+13.3%
Target 2 (3R)
₹46.89
+26.6%
Support (20d)
₹34.11
Resistance (52w)
₹56.88
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹3.28/share
ATR (volatility)
₹2.61
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹2.61). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental87
Technical30
Momentum23
Risk (safety)38

Peers — Pharma

CORONA 1.60%
87
GRANULES 1.12%
81
LAURUSLABS 1.23%
79
KPL 3.75%
79
DIVISLAB 1.23%
79
CAPLIPOINT 1.45%
78